Epigenetic Targets for Oligonucleotide Therapies of Pulmonary Arterial Hypertension
Arterial wall remodeling underlies increased pulmonary vascular resistance and right heart failure in pulmonary arterial hypertension (PAH). None of the established vasodilator drug therapies for PAH prevents or reverse established arterial wall thickening, stiffening, and hypercontractility. Theref...
Main Author: | William Gerthoffer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/23/9222 |
Similar Items
-
Epigenetics Approaches toward Precision Medicine for Idiopathic Pulmonary Fibrosis: Focus on DNA Methylation
by: Wiwin Is Effendi, et al.
Published: (2023-03-01) -
CCR7 and its related molecules may be potential biomarkers of pulmonary arterial hypertension
by: Mengsi Cai, et al.
Published: (2021-06-01) -
Molecular Insights into Epigenetics and Cannabinoid Receptors
by: Balapal S. Basavarajappa, et al.
Published: (2022-10-01) -
Insights on the epigenetic mechanisms underlying pulmonary arterial hypertension
by: R.C.P. Luna, et al.
Published: (2018-10-01) -
The Epigenetics of Migraine
by: Farzin Zobdeh, et al.
Published: (2023-05-01)